HRP20231183T1 - Optimizirani gen faktora viii - Google Patents
Optimizirani gen faktora viii Download PDFInfo
- Publication number
- HRP20231183T1 HRP20231183T1 HRP20231183TT HRP20231183T HRP20231183T1 HR P20231183 T1 HRP20231183 T1 HR P20231183T1 HR P20231183T T HRP20231183T T HR P20231183TT HR P20231183 T HRP20231183 T HR P20231183T HR P20231183 T1 HRP20231183 T1 HR P20231183T1
- Authority
- HR
- Croatia
- Prior art keywords
- nucleotide sequence
- seq
- vector
- nucleic acid
- acid molecule
- Prior art date
Links
- 229960000301 factor viii Drugs 0.000 title claims 5
- 108090000623 proteins and genes Proteins 0.000 title 1
- 239000002773 nucleotide Substances 0.000 claims 19
- 125000003729 nucleotide group Chemical group 0.000 claims 19
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 150000007523 nucleic acids Chemical class 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 108010054218 Factor VIII Proteins 0.000 claims 4
- 102000001690 Factor VIII Human genes 0.000 claims 4
- 230000000368 destabilizing effect Effects 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 108020004705 Codon Proteins 0.000 claims 2
- 230000006978 adaptation Effects 0.000 claims 2
- 208000031169 hemorrhagic disease Diseases 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 101100380342 Catharanthus roseus ASO gene Proteins 0.000 claims 1
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 208000031220 Hemophilia Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- 241000701447 unidentified baculovirus Species 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Claims (15)
1. Izolirana molekula nukleinske kiseline koja sadrži nukleotidnu sekvencu koja je najmanje 95%, najmanje 96%, najmanje 97%, najmanje 98%, najmanje 99%, ili 100% identična sa SEQ ID NO:2, pri čemu nukleotidna sekvenca kodira polipeptid s aktivnošću faktora VIII.
2. Izolirana molekula nukleinske kiseline prema patentnom zahtjevu 1, naznačena time što nukleotidna sekvenca sadrži SEQ ID NO:2.
3. Izolirana molekula nukleinske kiseline prema patentnom zahtjevu 1 ili 2, naznačena time što nukleotidna sekvenca kodira FVIII s izbrisanom B domenom.
4. Izolirana molekula nukleinske kiseline prema bilo kojem od zahtjeva 1 do 3, naznačena time što nukleotidna sekvenca ima jednu ili više od sljedećih karakteristika:
(a) nukleotidna sekvenca sadrži veći postotak G/C nukleotida u usporedbi sa SEQ ID NO:3;
(b) nukleotidna sekvenca sadrži manje MARS/ARS sekvenci (SEQ ID NO:5 i SEQ ID NO:6) u usporedbi sa SEQ ID NO:3;
(c) nukleotidna sekvenca ne sadrži mjesto spajanja GGTGAT (SEQ ID NO:7);
(d) nukleotidna sekvenca sadrži manje destabilizirajućih elemenata (SEQ ID NO:8 i SEQ ID NO:9) u odnosu na SEQ ID NO:3;
(e) nukleotidna sekvenca ne sadrži poli-T sekvencu (SEQ ID NO:10);
(f) nukleotidna sekvenca ne sadrži poli-A sekvencu (SEQ ID NO:11); ili
(g) indeks adaptacije humanog kodona je povećan u odnosu na SEQ ID NO:3.
5. Izolirana molekula nukleinske kiseline prema patentnom zahtjevu 4, naznačena time što
(a) indeks adaptacije humanog kodona je najmanje oko 0,75, najmanje oko 0,76, najmanje oko 0,77, najmanje oko 0,78, najmanje oko 0,79, najmanje oko 0,80, najmanje oko 0,81, najmanje oko 0,82, najmanje oko 0,83, najmanje oko 0,84, najmanje oko 0,85, najmanje oko 0,86, najmanje oko 0,87, ili najmanje oko 0,88;
(b) postotak G/C nukleotida je najmanje oko 45%, najmanje oko 46%, najmanje oko 47%, najmanje oko 48%, najmanje oko 49%, ili najmanje oko 50%;
(c) nukleotidna sekvenca:
(i) sadrži najviše jednu MARS/ARS sekvencu; ili
(ii) ne sadrži MARS/ARS sekvencu; i/ili
(d) nukleotidna sekvenca:
(i) sadrži najviše 4 destabilizirajuća elementa;
(ii) sadrži najviše 2 destabilizirajuća elementa; ili
(iii) ne sadrži destabilizirajući element.
6. Izolirana molekula nukleinske kiseline prema bilo kojem od patentnih zahtjeva 1-5, naznačena time što nadalje sadrži heterolognu nukleotidnu sekvencu.
7. Izolirana molekula nukleinske kiseline prema patentnom zahtjevu 6, naznačena time što je heterologna nukleotidna sekvenca kodira heterolognu aminokiselinsku sekvencu koja produživač vremena poluraspada.
8. Izolirana molekula nukleinske kiseline prema patentnom zahtjevu 7, naznačena time što je heterologna aminokiselinska sekvenca konstantna regija imunoglobulina ili njezin dio, transferin, albumin, ili PAS sekvenca; izborno pri čemu heterologna aminokiselinska sekvenca je Fc regija.
9. Izolirana molekula nukleinske kiseline prema patentnom zahtjevu 8, naznačena time što je heterologna aminokiselinska sekvenca povezana s N-terminalnim krajem ili C-terminalnim krajem aminokiselinske sekvence kodirane nukleotidnom sekvencom ili umetnuta između dvije aminokiseline u aminokiselinskoj sekvenci kodiranoj nukleotidnom sekvencom.
10. Vektor naznačen time što sadrži molekulu nukleinske kiseline prema bilo kojem od patentnih zahtjeva 1-9.
11. Vektor prema patentnom zahtjevu 10, naznačen time što je vektor adenovirusni vektor, lentivirusni vektor, bakulovirusni vektor, vektor virusa Epstein Barr, papovavirusni vektor, vektor vaccinia virusa, vektor virusa herpes simplex, ili vektor adeno povezanog virusa (AAV).
12. Stanica domaćina koja sadrži molekulu nukleinske kiseline prema bilo kojem od patentnih zahtjeva 1-9 ili vektor prema zahtjevu 10.
13. Polipeptid kodiran molekulom nukleinske kiseline prema bilo kojem od patentnih zahtjeva 1-9 ili vektorom iz zahtjeva 10 ili proizveden pomoću stanice domaćina prema zahtjevu 12.
14. Postupak za proizvodnju polipeptida s aktivnošću faktora VIII, naznačen time što obuhvaća: uzgoj stanice domaćina prema zahtjevu 12 pod uvjetima u kojima se proizvodi polipeptid s aktivnošću faktora VIII; te ponovno dobivanje polipeptida s aktivnošću faktora VIII.
15. Izolirana molekula nukleinske kiseline prema bilo kojem od patentnih zahtjeva 1-9, vektor iz zahtjeva 10, ili polipeptid iz zahtjeva 13 naznačen time što se koristi u liječenju poremećaja krvarenja kod subjekta kojem je to potrebno; izborno pri čemu je poremećaj krvarenja hemofilija.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361765626P | 2013-02-15 | 2013-02-15 | |
EP20204866.6A EP3889173B1 (en) | 2013-02-15 | 2014-02-14 | Optimized factor viii gene |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20231183T1 true HRP20231183T1 (hr) | 2024-01-05 |
Family
ID=51354568
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20231183TT HRP20231183T1 (hr) | 2013-02-15 | 2014-02-14 | Optimizirani gen faktora viii |
HRP20210185TT HRP20210185T1 (hr) | 2013-02-15 | 2021-02-02 | Optimizirani gen faktora viii |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20210185TT HRP20210185T1 (hr) | 2013-02-15 | 2021-02-02 | Optimizirani gen faktora viii |
Country Status (13)
Country | Link |
---|---|
US (3) | US10370431B2 (hr) |
EP (3) | EP4223772A3 (hr) |
DK (2) | DK2956477T4 (hr) |
ES (2) | ES2959747T3 (hr) |
FI (2) | FI2956477T4 (hr) |
HR (2) | HRP20231183T1 (hr) |
HU (2) | HUE063051T2 (hr) |
LT (2) | LT3889173T (hr) |
PL (2) | PL2956477T3 (hr) |
PT (2) | PT2956477T (hr) |
RS (2) | RS64664B1 (hr) |
SI (2) | SI2956477T1 (hr) |
WO (1) | WO2014127215A1 (hr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2956477T4 (da) | 2013-02-15 | 2024-04-15 | Bioverativ Therapeutics Inc | Optimeret faktor viii-gen |
SG11201701033QA (en) * | 2014-08-13 | 2017-03-30 | Philadelphia Children Hospital | An improved expression cassette for packaging and expression of variant factor viii for the treatment of hemostasis disorders |
EP3253786A4 (en) * | 2015-02-06 | 2018-10-17 | The University of North Carolina at Chapel Hill | Optimized human clotting factor viii gene expression cassettes and their use |
CN108093639B (zh) | 2015-04-16 | 2022-07-19 | 埃默里大学 | 用于肝脏中蛋白质表达的重组启动子和载体及其用途 |
EA036944B1 (ru) | 2015-11-13 | 2021-01-19 | Баксалта Инкорпорейтед | Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a |
SG11201804070XA (en) | 2015-11-13 | 2018-06-28 | Baxalta Inc | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a |
US11753461B2 (en) * | 2016-02-01 | 2023-09-12 | Bioverativ Therapeutics Inc. | Optimized factor VIII genes |
CA3055900A1 (en) * | 2016-03-20 | 2017-09-28 | The Trustees Of The University Of Pennsylvania | Codon optimization and ribosome profiling for increasing transgene expression in chloroplasts of higher plants |
KR20200118089A (ko) | 2018-02-01 | 2020-10-14 | 바이오버라티브 테라퓨틱스 인크. | 인자 viii을 발현하는 렌티바이러스 벡터의 용도 |
EP3823985A1 (en) | 2018-07-16 | 2021-05-26 | Baxalta Incorporated | Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression |
TW202039546A (zh) | 2019-01-16 | 2020-11-01 | 美商巴克斯歐塔公司 | 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體 |
CA3133255A1 (en) * | 2019-03-13 | 2020-09-17 | Generation Bio Co. | Non-viral dna vectors and uses thereof for expressing fviii therapeutics |
CN110295150A (zh) * | 2019-07-17 | 2019-10-01 | 天津润德生物科技有限公司 | 一类腺依赖病毒病毒重组质粒、重组病毒及构建方法 |
AU2020342349A1 (en) * | 2019-09-02 | 2022-03-03 | Biotest Ag | Factor VIII protein with increased half-life |
CN114981299A (zh) | 2019-12-12 | 2022-08-30 | 武田药品工业株式会社 | 使用编码具有增加的表达的重组fviii变体的病毒载体的a型血友病的基因疗法 |
CN117858895A (zh) | 2021-06-14 | 2024-04-09 | 武田药品工业株式会社 | 使用表达增强的编码重组fviii变体的病毒载体的血友病a基因疗法 |
IL310997A (en) * | 2021-08-23 | 2024-04-01 | Bioverativ Therapeutics Inc | Factor VIII gene optimization |
WO2023135273A2 (en) | 2022-01-14 | 2023-07-20 | Anjarium Biosciences Ag | Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof |
WO2023205300A2 (en) * | 2022-04-20 | 2023-10-26 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus using codon optimized nucleic acid encoding factor viii |
Family Cites Families (190)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
WO1986006101A1 (en) | 1985-04-12 | 1986-10-23 | Genetics Institute, Inc. | Novel procoagulant proteins |
KR910006424B1 (ko) | 1985-08-21 | 1991-08-24 | 인코텍스 비.브이 | 편성브리프(brief) 제조방법 |
EP0253870B1 (en) | 1986-01-03 | 1993-03-31 | Genetics Institute, Inc. | Method for producing factor viii:c-type proteins |
US5595886A (en) | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US5610278A (en) | 1986-06-24 | 1997-03-11 | Novo Nordisk A/S | Process for producing a coagulation active complex of factor VIII fragments |
EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
US6060447A (en) | 1987-05-19 | 2000-05-09 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
IE69026B1 (en) | 1987-06-12 | 1996-08-07 | Immuno Ag | Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
DE3720246A1 (de) | 1987-06-19 | 1988-12-29 | Behringwerke Ag | Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet |
FR2619314B1 (fr) | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
EP0461200B1 (en) | 1989-02-21 | 1997-01-22 | Washington University | Modified forms of reproductive hormones |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
PT669986E (pt) | 1992-11-13 | 2003-08-29 | Idec Pharma Corp | Sequencia do marcador de seleccao dominante alterada e estrategias de insercao intronica para melhoria de expressao de produto genico e sistemas de vector de expressao que o compreendem |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
US6818439B1 (en) | 1994-12-30 | 2004-11-16 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders |
US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
CA2262405A1 (en) | 1996-08-02 | 1998-02-12 | Bristol-Myers Squibb Company | A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
EP1696036B1 (en) | 1996-09-06 | 2010-04-21 | The Trustees of The University of Pennsylvania | Use of recombinant adeno-associated virus in the manufacture of a medicament for gene therapy via muscle cells |
GB9621680D0 (en) | 1996-10-17 | 1996-12-11 | Oxford Biomedica Ltd | Lentiviral vectors |
HUP0000421A2 (hu) | 1996-10-17 | 2000-06-28 | Oxford Biomedica (Uk) Limited | Retrovirális vektorok |
GB9622500D0 (en) | 1996-10-29 | 1997-01-08 | Oxford Biomedica Ltd | Therapeutic gene |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
CA2225189C (en) | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Canine factor viii gene, protein and methods of use |
PL191251B1 (pl) | 1997-03-14 | 2006-04-28 | Idec Pharma Corp | Sposób wprowadzania żądanego DNA w docelowe miejsce w genomie ssaka i układ wektorów |
US6207455B1 (en) | 1997-05-01 | 2001-03-27 | Lung-Ji Chang | Lentiviral vectors |
WO1999003496A1 (en) | 1997-07-21 | 1999-01-28 | The University Of North Carolina At Chapel Hill | Factor ix antihemophilic factor with increased clotting activity |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
JP2002510481A (ja) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | 抗体変異体及びその断片 |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
WO2000009560A2 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
US6924365B1 (en) * | 1998-09-29 | 2005-08-02 | Transkaryotic Therapies, Inc. | Optimized messenger RNA |
US20090042283A1 (en) * | 1998-09-29 | 2009-02-12 | Shire Human Genetic Therapies, Inc., A Delaware Corporation | Optimized messenger rna |
US6103526A (en) | 1998-10-08 | 2000-08-15 | Protein Sciences Corporation | Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using |
EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP1171624B1 (en) | 1999-04-29 | 2007-07-25 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
CA2401327C (en) | 2000-03-03 | 2014-05-06 | Valentis, Inc. | Nucleic acid formulations comprising poly-amino acids for gene delivery and methods of use |
WO2001079442A2 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7125841B2 (en) | 2000-11-14 | 2006-10-24 | The University Of Texas Systems | Mutant human factor IX with an increased resistance to inhibition by heparin |
GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
ES2649037T3 (es) | 2000-12-12 | 2018-01-09 | Medimmune, Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
US20020159978A1 (en) * | 2001-02-06 | 2002-10-31 | James Allen | Muscle-directed gene transfer by use of recombinant AAV-1 and AAV-6 virions |
US6888319B2 (en) | 2001-03-01 | 2005-05-03 | Palomar Medical Technologies, Inc. | Flashlamp drive circuit |
WO2002076489A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
US20040106794A1 (en) | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
WO2002092134A1 (en) | 2001-05-14 | 2002-11-21 | Cell Genesys, Inc. | Lentiviral vectors encoding clotting factors for gene therapy |
HUP0401534A3 (en) | 2001-09-04 | 2006-01-30 | Merck Patent Gmbh | Modified factor ix |
CA2467959C (en) | 2001-11-09 | 2009-03-10 | Robert M. Kotin | Production of adeno-associated virus in insect cells |
BRPI0214119B8 (pt) | 2001-11-13 | 2021-05-25 | Univ Pennsylvania | vírus adenoassociado recombinante, método de geração do referido vírus e composição compreendendo o referido vírus |
PT1453547T (pt) | 2001-12-17 | 2016-12-28 | Univ Pennsylvania | Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas |
US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
ES2500918T3 (es) | 2001-12-21 | 2014-10-01 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina e interferón beta |
KR101271635B1 (ko) | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
US6899917B2 (en) | 2001-12-27 | 2005-05-31 | 3M Innovative Properties Company | Powdered epoxy composition |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20040018557A1 (en) | 2002-03-01 | 2004-01-29 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
AU2002316574B2 (en) | 2002-03-15 | 2008-05-01 | Brandeis University | Central airway administration for systemic delivery of therapeutics |
US6615782B1 (en) | 2002-04-12 | 2003-09-09 | Delphi Technologies, Inc. | Two-step finger follower rocker arm |
WO2003100053A1 (en) | 2002-05-22 | 2003-12-04 | The Children's Hospital Of Philadelphia | Compositions and methods for the treatment of hemophilia a |
ATE536188T1 (de) | 2002-08-14 | 2011-12-15 | Macrogenics Inc | Fcgammariib-spezifische antikörper und verfahren zur verwendung davon |
ATE541857T1 (de) | 2002-09-27 | 2012-02-15 | Xencor Inc | Optimierte fc-varianten und herstellungsverfahren dafür |
JP4768439B2 (ja) | 2002-10-15 | 2011-09-07 | アボット バイオセラピューティクス コーポレイション | 変異誘発による抗体のFcRn結合親和力又は血清半減期の改変 |
GB2395337B (en) | 2002-11-14 | 2005-12-28 | Gary Michael Wilson | Warning Unit |
JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス,インコーポレーテッド | 変異型Fc領域を含む抗体の同定および作製ならびにその利用法 |
US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
DE602004010799T2 (de) | 2003-04-24 | 2009-01-22 | Fondazione Centro San Raffaele Del Monte Tabor | Synthetische bidirektionale promotoren und deren verwendungen |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
GB0325379D0 (en) | 2003-10-30 | 2003-12-03 | Oxford Biomedica Ltd | Vectors |
US20050249723A1 (en) | 2003-12-22 | 2005-11-10 | Xencor, Inc. | Fc polypeptides with novel Fc ligand binding sites |
BRPI0506771A (pt) | 2004-01-12 | 2007-05-22 | Applied Molecular Evolution | anticorpo, e, composição farmacêutica |
AU2005227326B2 (en) | 2004-03-24 | 2009-12-03 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
AU2005262329A1 (en) | 2004-07-01 | 2006-01-19 | Virxsys Corporation | Vector packaging cell line |
WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
EP3342782B1 (en) | 2004-07-15 | 2022-08-17 | Xencor, Inc. | Optimized fc variants |
US8030065B2 (en) | 2004-09-22 | 2011-10-04 | St. Jude Children's Research Hospital | Expression of factor IX in gene therapy vectors |
WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
CN101287834B (zh) | 2005-05-27 | 2016-11-09 | 圣拉法埃莱医院有限公司 | 基因载体 |
WO2007004670A1 (ja) | 2005-07-05 | 2007-01-11 | Kaneka Corporation | メタクリル系樹脂組成物 |
WO2007021494A2 (en) | 2005-08-12 | 2007-02-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
CA2622233C (en) | 2005-10-20 | 2015-01-20 | Amsterdam Molecular Therapeutics (Amt) B.V. | Improved aav vectors produced in insect cells |
US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
US8476234B2 (en) | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
JP5628481B2 (ja) | 2006-03-13 | 2014-11-19 | コーニンクレッカ フィリップス エヌ ヴェ | 固体照明システムのための適応制御装置及び方法 |
EP2848253A1 (en) | 2006-06-19 | 2015-03-18 | Asklepios Biopharmaceutical, Inc. | Modified factor VIII and factor IX genes and vectors for gene therapy |
EP2084274A2 (en) | 2006-06-19 | 2009-08-05 | Nautilus Technology LLC | Modified coagulation factor ix polypeptides and use thereof for treatment |
DK3023500T3 (da) | 2006-06-21 | 2020-04-20 | Uniqure Ip Bv | Insektceller til fremstilling af AAV-vektorer |
GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
US20100254944A1 (en) | 2006-09-14 | 2010-10-07 | Mani Subramanian | Albumin Fusion Proteins |
US7700734B2 (en) | 2007-01-09 | 2010-04-20 | Shu-Wha Lin | Recombinant human factor IX and use thereof |
CA2682605A1 (en) | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Single chain fc, methods of making and methods of treatment |
WO2008143954A2 (en) | 2007-05-14 | 2008-11-27 | Biogen Idec Ma Inc. | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
DK2173890T3 (da) | 2007-06-21 | 2011-06-27 | Univ Muenchen Tech | Biologisk aktive proteiner med forhøjet stabilitet in vivo og/eller in vitro |
WO2009051717A2 (en) | 2007-10-15 | 2009-04-23 | The University Of North Carolina At Chapel Hill | Human factor ix variants with an extended half life |
WO2009075772A1 (en) | 2007-12-06 | 2009-06-18 | Wyeth | Crystal structure of human factor viii and uses thereof |
WO2009137254A2 (en) | 2008-04-16 | 2009-11-12 | Bayer Healthcare Llc | Modified factor ix polypeptides and uses thereof |
CA2721362A1 (en) | 2008-04-16 | 2009-11-19 | Bayer Healthcare Llc | Site-directed modification of factor ix |
JP5665733B2 (ja) | 2008-04-21 | 2015-02-04 | ノボ ノルディスク ヘルス ケア アーゲー | 高度にグリコシル化されたヒト凝固第ix因子 |
US10273502B2 (en) | 2008-06-18 | 2019-04-30 | Oxford Biomedica (Uk) Limited | Virus purification |
ES2618851T3 (es) | 2008-06-18 | 2017-06-22 | Oxford Biomedica (Uk) Limited | Purificación de vectores retrovirales |
EP2149603A1 (en) | 2008-07-28 | 2010-02-03 | DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH | Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders |
PL3581650T3 (pl) | 2008-09-15 | 2023-05-22 | Uniqure Biopharma B.V. | Zmutowany polipeptyd czynnika ix, jego zastosowania i sposób jego wytwarzania |
WO2010055413A1 (en) | 2008-11-12 | 2010-05-20 | Fondazione Centro San Raffaele Del Monte Tabor | Gene vector for inducing transgene-specific immune tolerance |
NZ628987A (en) | 2009-02-03 | 2015-11-27 | Amunix Operating Inc | Extended recombinant polypeptides and compositions comprising same |
US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
US8716448B2 (en) | 2009-02-03 | 2014-05-06 | Amunix Operating Inc. | Coagulation factor VII compositions and methods of making and using same |
US9050269B2 (en) | 2009-03-10 | 2015-06-09 | The Trustees Of The University Of Pennsylvania | Protection of virus particles from phagocytosis by expression of CD47 |
WO2010115866A1 (en) | 2009-04-06 | 2010-10-14 | Novo Nordisk A/S | Targeted delivery of factor viii proteins to platelets |
US10287579B2 (en) | 2009-04-30 | 2019-05-14 | Ospedale San Raffaele S.R.L. | Gene vector |
US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
WO2010140148A1 (en) | 2009-06-01 | 2010-12-09 | Yeda Research And Development Co . Ltd | Prodrugs containing albumin binding probe |
NZ621868A (en) | 2009-06-08 | 2015-10-30 | Amunix Operating Inc | Growth hormone polypeptides and methods of making and using same |
CN102481331B (zh) | 2009-06-08 | 2017-09-22 | 阿穆尼克斯运营公司 | 葡萄糖调节多肽及其制备和使用方法 |
GB0911870D0 (en) * | 2009-07-08 | 2009-08-19 | Ucl Business Plc | Optimised coding sequence and promoter |
WO2011028344A2 (en) | 2009-08-25 | 2011-03-10 | Amunix Operating Inc. | Interleukin-1 receptor antagonist compositions and methods of making and using same |
SG179027A1 (en) | 2009-09-18 | 2012-04-27 | Micromet Ag | Dosage regimen for administering an epcamxcd3 bispecific antibody |
US8326547B2 (en) * | 2009-10-07 | 2012-12-04 | Nanjingjinsirui Science & Technology Biology Corp. | Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm |
US9050318B2 (en) * | 2009-12-06 | 2015-06-09 | Biogen Idec Hemophilia Inc. | Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof |
SG10201501285RA (en) | 2010-02-23 | 2015-04-29 | Sanofi Sa | Anti-alpha2 integrin antibodies and their uses |
WO2011133890A1 (en) | 2010-04-23 | 2011-10-27 | University Of Massachusetts | Cns targeting aav vectors and methods of use thereof |
WO2012006623A1 (en) | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Systems for factor viii processing and methods thereof |
AU2011274423B2 (en) | 2010-07-09 | 2016-02-11 | Bioverativ Therapeutics Inc. | Chimeric clotting factors |
SG10201505218YA (en) | 2010-07-09 | 2015-08-28 | Biogen Hemophilia Inc | Factor ix polypeptides and methods of use thereof |
US20130017997A1 (en) | 2010-08-19 | 2013-01-17 | Amunix Operating Inc. | Factor VIII Compositions and Methods of Making and Using Same |
AU2011298333B2 (en) | 2010-09-02 | 2015-05-14 | Molmed Spa | Stable production of lentiviral vectors |
CA2837995A1 (en) | 2011-06-03 | 2012-12-13 | The Regents Of The University Of Michigan | Method of producing factor viii proteins by recombinant methods |
EA029045B1 (ru) * | 2011-07-08 | 2018-02-28 | Байоджен Хемофилия Инк. | Химерные и гибридные полипептиды фактора viii и способы их применения |
AU2012340501A1 (en) * | 2011-12-19 | 2013-07-11 | Grifols, S.A. | Compositions, methods, and kits for preparing sialylated recombinant proteins |
NZ626945A (en) | 2012-01-12 | 2016-10-28 | Biogen Ma Inc | Chimeric factor viii polypeptides and uses thereof |
PT3564260T (pt) | 2012-02-15 | 2023-01-18 | Bioverativ Therapeutics Inc | Composições de fator viii e métodos de produção e utilização das mesmas |
KR20190094480A (ko) | 2012-02-15 | 2019-08-13 | 바이오버라티브 테라퓨틱스 인크. | 재조합 인자 viii 단백질 |
CN103316356B (zh) | 2012-03-22 | 2016-08-17 | 北京三诺佳邑生物技术有限责任公司 | 一种重组慢病毒载体制剂 |
US9192651B2 (en) | 2012-04-02 | 2015-11-24 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
AU2013270683A1 (en) | 2012-06-08 | 2014-12-11 | Biogen Ma Inc. | Chimeric clotting factors |
SG11201500045RA (en) | 2012-07-11 | 2015-02-27 | Amunix Operating Inc | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
RU2500816C1 (ru) | 2012-07-19 | 2013-12-10 | Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК рАК380, КОДИРУЮЩАЯ ПОЛИПЕПТИД РЕКОМБИНАНТНОГО ФАКТОРА IХ СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА, ЛИНИЯ КЛЕТОК Cricetulus griseus CHO 1E6 - ПРОДУЦЕНТ РЕКОМБИНАНТНОГО ФАКТОРА IХ СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА И СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА, ОБЛАДАЮЩЕГО АКТИВНОСТЬЮ РЕКОМБИНАНТНОГО ФАКТОРА IХ |
DK2956477T4 (da) * | 2013-02-15 | 2024-04-15 | Bioverativ Therapeutics Inc | Optimeret faktor viii-gen |
TWI667255B (zh) | 2013-08-14 | 2019-08-01 | 美商生物化學醫療公司 | 因子viii-xten融合物及其用途 |
EP2881463A1 (en) | 2013-12-09 | 2015-06-10 | DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH | Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders |
BR122023020301A2 (pt) | 2014-01-10 | 2023-12-12 | Bioverativ Therapeutics Inc. | Uso de uma proteína quimérica compreendendo uma proteína fviii |
US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
GB201412494D0 (en) | 2014-07-14 | 2014-08-27 | Ospedale San Raffaele And Fond Telethon | Vector production |
TWI707951B (zh) | 2015-04-08 | 2020-10-21 | 美商健臻公司 | 過大腺相關載體之製造 |
CN108093639B (zh) | 2015-04-16 | 2022-07-19 | 埃默里大学 | 用于肝脏中蛋白质表达的重组启动子和载体及其用途 |
WO2017024060A1 (en) | 2015-08-03 | 2017-02-09 | Biogen Ma Inc. | Factor ix fusion proteins and methods of making and using same |
IL296606A (en) | 2015-11-19 | 2022-11-01 | Novartis Ag | Buffers for stabilizing lentiviral preparations |
US11753461B2 (en) | 2016-02-01 | 2023-09-12 | Bioverativ Therapeutics Inc. | Optimized factor VIII genes |
JP2021512090A (ja) | 2018-01-30 | 2021-05-13 | モデルナティーエックス, インコーポレイテッド | 免疫細胞に薬剤を送達するための組成物及び方法 |
KR20200118089A (ko) | 2018-02-01 | 2020-10-14 | 바이오버라티브 테라퓨틱스 인크. | 인자 viii을 발현하는 렌티바이러스 벡터의 용도 |
US20220193222A1 (en) | 2018-11-30 | 2022-06-23 | Vaccine Stabilization Institute | Viral formulations containing amino acids |
CA3121786A1 (en) | 2018-12-06 | 2020-06-11 | Bioverativ Therapeutics Inc. | Use of lentiviral vectors expressing factor ix |
KR20220097891A (ko) | 2019-09-30 | 2022-07-08 | 바이오버라티브 테라퓨틱스 인크. | 렌티바이러스 벡터 제형 |
US20220033849A1 (en) | 2020-06-24 | 2022-02-03 | Bioverativ Therapeutics Inc. | Methods for the purification of viral vectors |
KR20230046323A (ko) | 2020-08-23 | 2023-04-05 | 바이오버라티브 테라퓨틱스 인크. | 폐쇄-말단 DNA(ceDNA)의 생산 개선을 위한 변형된 바큘로바이러스 시스템 |
-
2014
- 2014-02-14 DK DK14751254.5T patent/DK2956477T4/da active
- 2014-02-14 EP EP23165147.2A patent/EP4223772A3/en active Pending
- 2014-02-14 HR HRP20231183TT patent/HRP20231183T1/hr unknown
- 2014-02-14 ES ES20204866T patent/ES2959747T3/es active Active
- 2014-02-14 HU HUE20204866A patent/HUE063051T2/hu unknown
- 2014-02-14 LT LTEP20204866.6T patent/LT3889173T/lt unknown
- 2014-02-14 EP EP20204866.6A patent/EP3889173B1/en active Active
- 2014-02-14 LT LTEP14751254.5T patent/LT2956477T/lt unknown
- 2014-02-14 DK DK20204866.6T patent/DK3889173T3/da active
- 2014-02-14 FI FIEP14751254.5T patent/FI2956477T4/fi active
- 2014-02-14 EP EP14751254.5A patent/EP2956477B2/en active Active
- 2014-02-14 US US14/767,425 patent/US10370431B2/en active Active
- 2014-02-14 SI SI201431759T patent/SI2956477T1/sl unknown
- 2014-02-14 ES ES14751254T patent/ES2848703T3/es active Active
- 2014-02-14 RS RS20230892A patent/RS64664B1/sr unknown
- 2014-02-14 PT PT147512545T patent/PT2956477T/pt unknown
- 2014-02-14 PT PT202048666T patent/PT3889173T/pt unknown
- 2014-02-14 HU HUE14751254A patent/HUE053136T2/hu unknown
- 2014-02-14 PL PL14751254T patent/PL2956477T3/pl unknown
- 2014-02-14 PL PL20204866.6T patent/PL3889173T3/pl unknown
- 2014-02-14 RS RS20210126A patent/RS61387B1/sr unknown
- 2014-02-14 FI FIEP20204866.6T patent/FI3889173T3/fi active
- 2014-02-14 SI SI201432044T patent/SI3889173T1/sl unknown
- 2014-02-14 WO PCT/US2014/016441 patent/WO2014127215A1/en active Application Filing
-
2019
- 2019-06-25 US US16/452,010 patent/US11787851B2/en active Active
-
2021
- 2021-02-02 HR HRP20210185TT patent/HRP20210185T1/hr unknown
-
2023
- 2023-09-06 US US18/461,697 patent/US20240141019A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
PT2956477T (pt) | 2021-02-05 |
FI2956477T4 (fi) | 2024-04-24 |
US10370431B2 (en) | 2019-08-06 |
US20150361158A1 (en) | 2015-12-17 |
RS61387B1 (sr) | 2021-02-26 |
US20200024327A1 (en) | 2020-01-23 |
EP2956477B1 (en) | 2020-11-18 |
PL3889173T3 (pl) | 2023-12-11 |
US20240141019A1 (en) | 2024-05-02 |
FI3889173T3 (fi) | 2023-10-02 |
EP2956477B2 (en) | 2024-01-24 |
ES2959747T3 (es) | 2024-02-28 |
US11787851B2 (en) | 2023-10-17 |
SI3889173T1 (sl) | 2023-11-30 |
LT3889173T (lt) | 2023-10-10 |
HUE053136T2 (hu) | 2021-06-28 |
RS64664B1 (sr) | 2023-11-30 |
HUE063051T2 (hu) | 2023-12-28 |
EP4223772A2 (en) | 2023-08-09 |
DK2956477T3 (da) | 2021-02-08 |
PL2956477T3 (pl) | 2021-06-14 |
DK3889173T3 (da) | 2023-10-09 |
EP2956477A1 (en) | 2015-12-23 |
DK2956477T4 (da) | 2024-04-15 |
EP3889173B1 (en) | 2023-07-05 |
ES2848703T3 (es) | 2021-08-11 |
EP4223772A3 (en) | 2023-10-18 |
HRP20210185T1 (hr) | 2021-03-19 |
EP3889173A1 (en) | 2021-10-06 |
SI2956477T1 (sl) | 2021-03-31 |
EP2956477A4 (en) | 2016-12-28 |
WO2014127215A1 (en) | 2014-08-21 |
PT3889173T (pt) | 2023-10-10 |
LT2956477T (lt) | 2021-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20210185T1 (hr) | Optimizirani gen faktora viii | |
HRP20221089T1 (hr) | Optimizirani geni faktora viii | |
CL2019002280A1 (es) | Vectores virales, adenovirales y composiciones a base de una secuencia de ornitina transcarbamilasa humana (hotch) modificada genéticamente y su uso en el tratamiento de deficiencia de la otc. (divisional solicitud 201602235) | |
JP2018537087A5 (hr) | ||
HRP20201614T1 (hr) | Novi imunoadhezini ctla4-ig | |
DK1976871T3 (da) | Vacciner og immunterapeutika under anvendelse af codonoptimerede IL-15 og fremgangsmåder til anvendelse deraf | |
ES2548030T3 (es) | Moléculas con semividas prolongadas y usos de las mismas | |
JP2019506166A5 (hr) | ||
JP2021501581A5 (hr) | ||
JP2020522259A5 (hr) | ||
JP2017018125A5 (hr) | ||
HRP20231496T1 (hr) | Cistein proteaza | |
NZ603348A (en) | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof | |
JP2015521465A5 (hr) | ||
JP2019536462A5 (hr) | ||
RU2004136574A (ru) | Транскрипционная регуляторная днк гена хомяка ef-1 | |
JP2020518268A5 (hr) | ||
JP2020520662A5 (hr) | ||
JP2013502226A5 (hr) | ||
JP2013509168A5 (hr) | ||
CA2814947C (en) | Fusion protein with factor ix activity | |
JP2018537089A5 (hr) | ||
PE20221254A1 (es) | Proteina vp1 modificada aislada de la capside del virus adeno-asociado de serotipo 5 (aav5), capside y vector basado en la misma | |
JP2020529221A5 (hr) | ||
KR101713407B1 (ko) | 아데노바이러스 감염 및 복제가 가능한 흑색종 세포주 |